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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of altering total polyunsaturated fat intake on cardiovascular disease, and other health outcomes, in adults.
B A C K G R O U N D
Description of the condition
The World Health Organization (WHO) reports cardiovascular
diseases (CVDs) as the primary cause of death in the world (WHO
2016). In 2012 they estimated that 17.5 million people died from
cardiovascular diseases, three-quarters of whom were in low- to
middle-income countries. Cardiovascular diseases are disorders of
the heart andblood vessels and include a range of conditions. Some
are diseases of blood vessels supplying the heart (coronary heart
disease), brain (cerebrovascular disease), or arms or legs (periph-
eral arterial disease). Others are due to infection (rheumatic heart
disease, where damage to the heart muscle and valves is due to
rheumatic fever), or are present at birth (congenital heart disease),
or are due to blood clots (deep vein thrombosis and pulmonary
embolism) (WHO2016). This review is concernedwith the forms
of cardiovascular disease that are potentially modifiable by dietary
means, particularly coronary heart disease and cerebrovascular dis-
ease.
Description of the intervention
Polyunsaturated fatty acids (PUFAs) are fats that include at least
two double carbon-to-carbon bonds (unsaturated carbon bonds)
in their long hydrocarbon chain. This makes the fats pack less
well, so they tend to be liquid at room temperature, rather than
solid like many saturated fats. PUFAs can be omega-3 (where the
first double bond is three carbons away from the methyl-carbon
end of the molecule), omega-6 or omega-9. Plant and fish oils are
often rich in PUFAs, with fish being rich in omega-3 and plant
oils rich in omega-6. Two PUFAs, alpha-linolenic acid (omega-3)
and linoleic acid (omega-6), are essential nutrients in humans.
Dietary fats have been implicated in cardiovascular health since
Keys published his groundbreaking study linking plasma choles-
terol and dietary saturated fat (Keys 1950), and Oliver reported
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higher levels of lower density lipid (LDL) cholesterol in those sur-
viving myocardial infarction compared to controls without my-
ocardial infarction (Oliver 1953). In 1965 Hegsted published
an equation that quantified the relationship between dietary fat
and serum total cholesterol, suggesting that increasing saturated
fats increased serum cholesterol, while increasing PUFAs reduced
serum cholesterol (Hegsted 1965). More recently there was dis-
cussion about what type of PUFA may be protective, with interest
in omega-3 PUFAs following ground-breaking randomized con-
trolled trials (RCTs) with dietary fish and fish oil supplementation
interventions in the 1980s and 1990s(Burr 1989; GISSI-P 1999),
although subsequent trials have been equivocal (Hooper 2004).
Similarly, while there are good theoretical grounds for suggesting
that omega-6 fatsmay be protective against cardiovascular diseases,
the RCT evidence is limited (Al-Khudairy 2015). However, there
is evidence that replacing saturated fats with PUFAs does protect
against cardiovascular disease, and that PUFAs appear to be more
protective than reducing saturated fats and replacing them with
carbohydrates (Hooper 2015a). On the other hand, reducing di-
etary fat (including PUFAs) appears to result in lower weight in
adults, suggesting that lower PUFA intake would tend to protect
against cardiovascular disease (Hooper 2015b).
How the intervention might work
PUFAs are generally thought to work by producing a reduction
in serum total and LDL cholesterol, which slows the progress of
atherosclerosis (a complex syndrome in which plaque builds up
inside the arteries over time, reducing blood flow and leading to
an increased risk of blood clots), and so delays or prevents the
onset of cardiovascular and cerebrovascular disease. This theory is
reinforced by evidence that replacing saturated fats with polyun-
saturated fats is associated with greater reductions in cardiovas-
cular events and with greater serum total cholesterol reduction
(Hooper 2015a). Additional modes of action have been proposed
for omega-3 PUFAs, these include: lowering of blood pressure; re-
ducing thrombotic tendency; anti-inflammatory and antiarrhyth-
mic effects; improving vascular endothelial function; increasing
plaque stability (through increased plaque calcification); and im-
proving insulin sensitivity (Calder 2012; Ohwada 2016). Omega-
6 PUFAs may reflect the general lipid-lowering effects of PU-
FAs, but there has been concern that high levels of omega-6 in-
take can increase production of 2-series prostaglandins and 4-se-
ries leukotrienes compared with the 3-series prostaglandins and
5-series leukotrienes associated with omega-3 intake. As the 2-se-
ries prostaglandins and 4-series leukotrienes exert a more potent
proinflammatory effect, omega-6 could increase the risk of car-
diovascular disease via this mechanism (Russo 2009).
Why it is important to do this review
The evidence on the health effects of total PUFA intake, which
is the combination of omega-3 and omega-6 fats, is equivocal. As
cardiovascular diseases are such important determinants of health,
that place a particular burden on the poorest people (WHO2016),
it is vital that we understand the role of PUFAs in them so that
we can provide the best advice for individuals and populations
about how to eat to reduce the risk of ill health. This assessment
of the health effects of total PUFA intake is needed alongside
updated assessment of the effects of omega-3 and omega-6 fats
specifically (Al-Khudairy 2015; Hooper 2004). This review will
assess the overall impact of increasing total PUFA intake and will
be interpreted in the light of effects on health of increasing omega-
3 fats (in the planned update of Hooper 2004) and of increasing
omega-6 fats (in the planned update of Al-Khudairy 2015).
O B J E C T I V E S
To assess the effects of altering total polyunsaturated fat intake on
cardiovascular disease, and other health outcomes, in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomized controlled trials (RCTs) that compare
higher with lower polyunsaturated fat intakes, randomise at least
100 participants, and assess effects over at least 12months.We will
include studies reported as full-text, those published as abstracts
only, and unpublished data. We will not include cross-over studies
(as this design is inappropriate for outcomes such as cardiovascular
disease events or mortality), but will include cluster-randomised
studies, as long as there are at least six clusters.
Small trials that randomise fewer than 100 participants will be
excluded due to concerns over small study bias and the consequent
potential for random error to result in false positive conclusions
(Roberts 2015).
Types of participants
We will include studies of adults (18 years of age and above), ex-
cept those who are pregnant or acutely ill. Specifically, we will in-
clude studies of adults (18 years or older, men or women or both)
at any risk of cardiovascular disease (with or without existing car-
diovascular disease). Included participants can be adults with in-
creased risk of cancer, those undergoing - or who have undergone
- coronary artery bypass grafting or angioplasty, and those with
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current or previous cardiovascular disease, nephritis in systemic
lupus erythematosus, diabetes mellitus, rheumatoid arthritis, de-
pression, cognitive impairment, or multiple sclerosis.
We will exclude participants who are pregnant or acutely ill
(those with diagnosed current cancer, undergoing heart or re-
nal transplantation, with HIV or AIDS, on haemodialysis, with
immunoglobulin A (IgA) glomerulonephritis, or any other renal
problem except in diabetes).
Where trials include some adults and some people under 18 years
of age, then the studywill be included if at least 90%of participants
were aged 18 years or over at baseline, or where outcomes for adults
can be separated from those for younger people.
Types of interventions
Eligible trials will compare higher with lower total polyunsatu-
rated fat (PUFA) intakes. The intervention must be either dietary
supplementation, or a provided diet, or advice on diet. The ad-
vice, foodstuffs or supplements must aim to increase or decrease
total PUFA intake, or, if no clear aim is stated (but implied, such
as aiming to provide a ’heart health’ or ’Mediterranean’ diet) then
the intervention must achieve an increase or decrease of at least
10% of the baseline total PUFA level.
Supplementation may be in oil or capsule form, or as food-stuffs
provided, to be consumed by mouth (we will exclude enteral and
parenteral feeds, and enemas). Studies will not be included if they
include a multiple risk factor intervention on lifestyle factors other
than diet and supplementation (unless the effect of diet or supple-
mentation could be separated out from the other interventions).
Where the alteration of PUFA intake is only part of a dietary inter-
vention (such as a combined intervention to increase PUFA and
fruit and vegetable intake) the study will be included.
Studies will be included if they compared the effect of this inter-
vention with usual diet, no advice, no supplementation or placebo
(as appropriate) or with the opposite intervention (raised versus
lowered PUFA intake).
Types of outcome measures
Primary outcomes
These outcomes have been requested by the WHO Nutrition
Guidance Expert Advisory Group (NUGAG) to inform their
planned dietary guidance. Dichotomous outcomes will be assessed
at the latest point of available follow-up within the RCT while
continuous outcomes will be assessed at one year and at the latest
point in the trial.
Primary outcomes will be:
1. all-cause mortality;
2. major adverse cardiac and cerebrovascular events
(MACCEs) or cardiovascular events: death, myocardial
infarction, unstable angina or stroke;
3. coronary heart disease events: myocardial infarction (fatal
or non-fatal) or angina;
4. stroke (total, ischaemic and haemorrhagic).
Secondary outcomes
Secondary outcomes will include:
1. cardiovascular mortality;
2. myocardial infarction;
3. sudden death;
4. angina;
5. heart failure;
6. peripheral vascular events;
7. atrial fibrillation;
8. revascularisation, angioplasty or coronary artery bypass
grafting;
9. body weight and measures of adiposity;
10. type 2 diabetes;
11. serum lipids (including total cholesterol, fasting
triglycerides, high-density lipid (HDL) cholesterol and LDL
cholesterol);
12. blood pressure (systolic and diastolic);
13. quality of life measures (such as feelings of health and time
off work);
14. economic costs;
15. serious adverse events (including breast cancer, all cancers,
inflammatory bowel disease, neurocognitive outcomes such as
dementia, and depression).
Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases:
1. Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
2. MEDLINE (Ovid);
3. Embase (Ovid).
The preliminary search strategy forMEDLINE (Ovid) (Appendix
1) was adapted from the search strategy in Al-Khudairy 2015 and
is also being used to update Al-Khudairy 2015. This complex strat-
egy will be adapted for use in the other databases. The Cochrane
sensitivity and precision-maximising RCT filter will be applied to
MEDLINE (Ovid) and for Embase, and terms recommended in
the Cochrane Handbook for Systematic Reviews of Interventions will
be applied (Lefebvre 2011).
We will also conduct a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the WHO International Clinical
Trials Registry Platform (ICTRP) Search Portal (apps.who.int/
trialsearch/).
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We will search all databases from their inception to the present,
and we will impose no restriction on language of publication.
Searching other resources
We will check reference lists of all included primary studies and
relevant systematic reviews for additional references.
We will contact the authors of all RCTs that compare our interven-
tion and control, randomise at least 100 participants, and follow
them up for at least 12 months, to request available data on all of
the review outcomes. Where data on at least one review outcome
are available, the RCT will be included, and the authors asked to
provide any additional data about study methodology or risk of
bias.
Data collection and analysis
Selection of studies
Two review authors will independently screen titles and abstracts
for inclusion of all the potential studies we identify as a result of the
search and code them as ’retrieve’ (eligible or potentially eligible/
unclear) or ’do not retrieve’. If there are any disagreements, a third
author will be asked to arbitrate (LH). We will retrieve the full-
text study reports/publication and two review authors will inde-
pendently screen the full-text, identify studies for inclusion, and
identify and record reasons for exclusion of ineligible studies. We
will resolve any disagreement through discussion or, if required,
we will consult a third person (LH). We will identify and exclude
duplicates and collate multiple reports of the same study so that
each study - rather than each report - is the unit of interest in
the review. We will record the selection process in sufficient detail
to complete a PRISMA flow diagram and ’Characteristics of ex-
cluded studies’ table.
Data extraction and management
Wewill use a data collection form for collating study characteristics
and outcome data that has been piloted on at least one study in
the review. Two review authors will extract the following study
characteristics from included studies:
1. bibliographic details;
2. trial registration number;
3. methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study;
4. participants: number randomized in each arm, number
analyzed in each arm, mean age, age range, gender, health status,
baseline cardiovascular disease risk, inclusion criteria, and
exclusion criteria. Baseline cardiovascular risk will be categorised
as low (no specific cardiovascular disease risk factors in the
inclusion criteria), moderate (people recruited on the basis of
hyperlipidaemia, diabetes, metabolic syndrome, familial risk,
high blood pressure, obesity or a high cardiovascular disease risk
score), or high (those with existing cardiovascular disease such as
angina or a previous stroke or myocardial infarction);
5. interventions: intervention (including composition and
dose of PUFA intake advised or supplement used), comparison,
concomitant medications, and excluded medications;
6. outcomes: primary and secondary outcomes specified in
trial registry, data on outcomes reported in publications and by
contact with authors, time points reported;
7. process data: mean and standard deviation (SD) of total
PUFA, omega-3, omega-6, total fat, saturated fat (SFA),
monounsaturated fat (MUFA) and trans fat intake plus
erythrocyte, serum or adipose tissue fatty acid status data in
intervention and control groups at latest point available during
RCT;
8. trial funding and notable conflicts of interest of trial
authors.
Two review authors will independently extract outcome data from
included studies. We will resolve disagreements by consensus or
by involving a third person (LH). One review author will transfer
data into the Review Manager 5 file (RevMan 2014). We will
double-check that data are entered correctly by comparing the
data presented in the systematic review with the study reports.
A second review author will spot-check study characteristics for
accuracy against the trial reports.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study, alongside data extraction, using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We will resolve any disagreements by discussion or by in-
volving another author. We will assess the risk of bias according
to the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. industry funding;
8. preregistered on a trials register (registration date is before
outcome data collection begins; Roberts 2015);
9. attention bias (another aspect of performance bias, where
the intervention or control groups receive more time and
attention from study or health personnel, or both, during the
trial);
10. clear PUFA causality (another aspect of performance bias,
where a study intervention included changes other than the
change in PUFA intake, when there would be high risk of bias).
4Polyunsaturated fat intake for prevention of cardiovascular disease (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We will grade each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgment in the ’Risk of bias’ tables. We will sum-
marize the risk of bias judgements across different studies for each
of the domains listed. Where information on risk of bias relates to
unpublished data or correspondence with a trialist, we will note
this in the ’Risk of bias’ tables.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as risk ratios with 95% confi-
dence intervals and continuous data as mean differences (or stan-
dardised mean differences when different scales that measure the
same effects are combined) with 95% confidence intervals. We
will enter data presented as a scale with a consistent direction of
effect. We will describe skewed data reported as medians and in-
terquartile ranges narratively.
Unit of analysis issues
If we include cluster randomized trials we will account for unit of
analysis issues by data extracting a direct estimate of the required
effect measure (for example, a risk ratio with its confidence inter-
val) from an analysis that accounts for the cluster design properly
(for example, an analysis based on a ‘multilevel model’, a ‘variance
components analysis’ or that uses ‘generalised estimating equa-
tions (GEEs)’). If these data are available then we will use them in
meta-analysis using the generic inverse-variance method (Higgins
2011). Where no such correct analysis of the cluster-randomised
data are available, we will use approximate analyses using intra-
cluster correlation co-efficient (ICC) analysis as outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011, section 16.3.4)
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics, including those related to risk of bias. We
will try to contact the authors of all included trials to request data
on all relevant outcomes reported in their trial registry entry, or,
where no trial registry entry can be found, we will ask for data on
all of our review outcomes (primary and secondary). We will use
this to obtain any missing numerical outcome data where possible.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity (as-
sumed when I2 is greater than 50%) we will report it and explore
possible causes by prespecified subgroup analysis.
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and
examine a funnel plot to explore possible reporting biases for the
primary outcomes.
Data synthesis
Wewill undertakemeta-analyses only where this ismeaningful, i.e.
if the treatments, participants and the underlying clinical question
are similar enough for pooling tomake sense.Our primary analyses
will assess effects of dietary (dietary advice or supplemental foods
such as fortifiedmargarine provided by the study) or supplemental
sources (capsules or oils) of total PUFA separately.
We will use a random-effects model, as dietary interventions are
complex and somewhat heterogeneous by their nature (more so
than most medical treatments), but we will compare the results of
random-effects and fixed-effect meta-analysis in sensitivity analy-
ses. As the random-effects model assigns more weight to smaller
studies, it is more conservative andmay lead to imprecise estimates
of effect. However, as very small trials (randomising fewer than
100 participants) will not be included in this review, the risk of ob-
scuring an important answer is minimised. We will also carry out
sensitivity analyses to assess the effects of methodological rigour,
as well as study size.
’Summary of findings’ table
We will create a ’Summary of findings’ table using the following
outcomes:
1. all-cause mortality;
2. major adverse cardiac and cerebrovascular events;
3. coronary heart disease events;
4. stroke, total;
5. cardiovascular mortality;
6. type 2 diabetes;
7. serious adverse events (including breast cancer, all cancers,
inflammatory bowel disease, neurocognitive outcomes such as
dementia, and depression).
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness and publication
bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data to the meta-analyses for the pre-
specified outcomes. We will use methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), and use
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GRADEpro GDT software (GRADEpro GDT 2014). We will
justify all decisions to downgrade the quality of studies using foot-
notes and we will make comments to aid reader’s understanding
of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We will explore the effects of PUFA intake on primary outcomes
by performing subgroup analyses on:
1. total PUFA dose (and dose response);
2. trial duration: studies with medium follow-up (12 to 23
months), medium to long follow-up (24 to 47 months), and
long follow-up (48 months or more);
3. baseline total PUFA intake;
4. replacement of SFA with total PUFA;
5. replacement of MUFA with total PUFA;
6. for total PUFA: at least 6% of energy versus lower levels of
intake, at least 11% of energy versus lower levels of intake;
7. PUFA dose response;
8. change in the omega-3:omega-6 ratio: does this
intervention primarily increase omega-3 (putting up the ratio) or
omega-6 (lowering the ratio)?
9. age;
10. sex;
11. baseline risk of cardiovascular disease.
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
For primary outcomes where sufficient trials (at least 10) are iden-
tified as suitable for meta-analysis, we will use meta-regression to
explore the effects of PUFA dose, serum PUFA levels, baseline
PUFA intake, omega-3:omega-6 ratio, supplemental or dietary
source and trial duration.
Sensitivity analysis
We plan to carry out the following sensitivity analyses:
1. using fixed-effect meta-analysis;
2. only including studies with a low risk of bias for allocation
concealment;
3. only including all studies up to 2010, plus studies post-
2010 that are registered on a trials register (Roberts 2015);
4. only including studies with no industry funding;
5. only including studies with less than 10% difference in
intake of trans fats between study arms during the intervention;
6. only including studies with a low risk of attention bias;
7. only including studies which randomized at least 250
participants.
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
will avoid making recommendations for practice and our impli-
cations for research will suggest priorities for future research and
outline what the remaining uncertainties are in the area.
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A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1. exp fatty acids, essential/
2. fatty acids, unsaturated/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. exp fatty acids, omega-6/
7. omega-6.ti,ab.
8. (n-6 adj4 acid*).ti,ab.
9. linoleic acid*.ti,ab.
10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/
11. ((corn or maize or mazola) adj4 oil*).ti,ab.
12. (cottonseed* or (cotton adj seed*)).ti,ab.
13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
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15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
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